Phase 2 N=60 Temozolomide in Treating Patients With Recurrent High-Grade Glioma
Recurrent Central Nervous System Neoplasm
Primary: 6 Month Progression-free Survival — 10; 50 percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=62 Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
Primary: ORR — 0; 0; 0; 0 percentage of patients
Phase 2 N=31 Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM
Glioblastoma Multiforme · Brain Tumor
Primary: Progression-free Survival (PFS) — 91.3 percentage of participants
Phase 2 N=31 Low Dose Radiation Therapy for Glioblastoma Multiforme
High Grade Glioma
Primary: Response Rate
Phase 3 N=749 A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma
Newly Diagnosed Glioblastoma
Primary: Overall Survival (OS) — 16.13; 15.08 Months
Phase 2 N=37 BIBF 1120 for Recurrent High-Grade Gliomas
Glioblastoma · Gliosarcoma · Anaplastic Astrocytoma
Primary: 6-Month Progression Free Survival — 0 percentage of participants
Phase 1 N=16 Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) — 0; 0; 0; 1 Participants
N/A N=20 Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma
Adult Glioblastoma
Primary: Number of Participants Who Received Treatment Recommendations Within 35 Days of Surgery — 15 Participants
Phase 2 N=58 Dose-Intense Temozolomide in Recurrent Glioblastoma
Glioblastoma · Gliosarcoma
Primary: 6 Month Progression Free Survival — 11 percentage of evaluable participants
Phase 2 N=58 Everolimus in Treating Patients With Recurrent Low-Grade Glioma
Adult Diffuse Astrocytoma · Adult Mixed Glioma · Adult Oligodendroglioma
Primary: Progression-free Survival at 6 Months. — 39; 6 Participants
Phase 2 N=151 A Study in Subjects With Recurrent Malignant Glioma
Glioma
Primary: Progression Free Survival (PFS) Rate at Month 6 — 11.0; 21.2; 8.0; 7.6 Percentage of participants
Phase 2 N=177 Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
High Grade Glioma · Astrocytoma, Grade III · Glioblastoma
Primary: Phase 1: Maximum Tolerated Dose (MTD) of BMX-001 Administered in Combination With Standard RT and TMZ in Newly Diagnosed HGG Patients — NA mg/Participant
Phase 3 N=1,125 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Brain and Central Nervous System Tumors
Primary: Median Overall Survival Time — 16.6; 14.9 months — p=0.63
Phase 2 N=10 Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma
MGMT-unmethylated Glioblastoma (GBM) · GBM
Primary: 1-year Overall Survival (OS) — 80 percentage of participants
Phase 2 N=20 Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma
Anaplastic Astrocytomas · Anaplastic Oligodendrogliomas · Glioblastomas (GBM)
Primary: Progression Free Survival, Assessed by Revised Assessment in Neuro-oncology (RANO) Criteria — 11 participants
Phase 2 N=38 A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
Adult Anaplastic Astrocytoma · Adult Giant Cell Glioblastoma · Adult Gliosarcoma
Primary: Number of Dose Limiting Toxicity to Determine Maximum Tolerated Dose (MTD) of BMS-247550 in Patients With Recurrent or Progressive Malignant Glioma — 0; 0; NA; 0 DLTs
Phase 2 N=121 Lerapolturev in Recurrent Malignant Glioma
Malignant Glioma
Primary: Number of Participants With Objective Radiographic Response — 5; 2 Participants
Phase 2 N=123 Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
Adult Glioblastoma · Adult Gliosarcoma · Recurrent Adult Brain Neoplasm
Primary: Count/Percentage of Patients Progression-free at 6 Months for Bevacizumab and Irinotecan Hydrochloride Arm — 22 Participants
Phase 2 N=88 Bevacizumab for Recurrent Malignant Glioma
Recurrent High-Grade Gliomas · Malignant Gliomas
Primary: Percentage of Participants With Progression Free Survival at 6 Months. — 20.9; 29 Percentage of participants
Phase 3 N=35 Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
Recurrent or Progressive Glioblastoma
Primary: Local Tumor Control — 14; 4 Participants
Phase 2 N=158 A Study in Recurrent Glioblastoma (GB)
Glioblastoma
Primary: Overall Survival (OS) — 8.0; 6.7; 7.5 Months
Phase 2 N=68 Bevacizumab Beyond Progression (BBP)
Malignant Glioma · Grade 4 Malignant Glioma · Glioblastoma
Primary: Overall Survival — 17.8 months
Phase 2 N=25 Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma
Glioblastoma · Astrocytoma · Oligodendroglioma
Primary: Progression-free Survival at 6-months — 17.3 percentage of participants
Phase 2 N=47 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
Brain and Central Nervous System Tumors
Primary: Progression-free Survival (PFS) Rate at 6 Months — 19 percentage of participants
Phase 2 N=30 Study of Capecitabine to Treat Recurrent High Grade Gliomas
Malignant Glioma
Primary: Percentage of Participants With Progression-free Survival. — 21.7 percentage of participants with PFS6
Phase 2 N=50 FR901228 in Treating Patients With Recurrent High-Grade Gliomas
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Number of Participants With Dose-limiting Toxicities Due to Romidepsin Graded According to the NCI Common Toxicity Criteria (CTCAE Version 3.0) (Phase I) — 0 participants
Phase 2 N=66 BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
IDH1 Mutation · IDH2 Mutation · Recurrent Glioblastoma
Primary: Participants With Dose Limiting Toxicity (DLT) Rate Less Than or Equal to 33% (Dose Level 1) — 0; 7 Participants
Phase 1 N=24 IDH1 Peptide Vaccine for Recurrent Grade II Glioma
Brain Cancer · Brain Neoplasm, Primary · Brain Neoplasms, Recurrent
Primary: Percentage of Participants With an Unacceptable Toxicity — 0 percentage of participants
Phase 2 N=33 Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
Gliomas
Primary: Overall Response Rate — 9 percent
Phase 2 N=97 Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM
Glioblastoma Multiforme
Primary: Survival — 17.2 months — p=>.1